1. Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kosters JP, Vacca C, Machado M, Diaz Ayala DH, Oxman AD. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2014;(10):CD005979. https://doi.org/10.1002/14651858.CD005979.pub2.
2. Australian Government Department of Health. Review of pharmaceutical benefits scheme anti-dementia drugs to treat Alzheimers disease. Australian Government Department of Health. 2012. Available via https://www.pbs.gov.au/info/reviews/anti-dementia-drugs. Accessed 13 July 2021.
3. Australian Government Department of Health. Post-market reviews of pharmaceutical benefits scheme subsidised medicines, Department of Health. 2015. Available via https://www.pbs.gov.au/info/reviews/subsidised-medicines-reviews. Accessed 21 July 2021.
4. Australian Government Department of Health. PBS expenditure and prescriptions, Australian Government Department of Health. 2020. Available via https://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions. Accessed 9 July 2021.
5. Australian Government Department of Health. Drug utilisation subcommittee, Department of Health. 2021. Available via https://www.pbs.gov.au/pbs/industry/listing/participants/drug-utilisation-subcommittee. Accessed 13 July 2021.